GenAI
LATEST
Menarini Group and Insilico Medicine Enter a Second Exclusive Global License Agreement for an AI Discovered Preclinical Asset Targeting High Unmet Needs in Oncology
2025-01-10
Posdinemab Becomes J&J’s Second FDA Fast Track Designation Targeting Phosphorylated Tau in Alzheimer’s Disease
2025-01-09